—
GHRH + GHRP Synergy
Various
Combinations of GHRH analogs with GHRPs are widely studied for synergistic effects on GH-release amplitude.
Featured Blend
Lot CB26-04-009MFG 04/2026
About CJC-1295 / Ipamorelin
A two-component combination blend of CJC-1295 (no DAC) and Ipamorelin at 5 mg of each in a single 10 mg lyophilized vial. The combination pairs a modified GHRH 1-29 analog (CJC-1295 No DAC) with a selective ghrelin-receptor agonist (Ipamorelin) — a pairing widely studied in research models of synergistic GH release.
Component peptides are individually verified for identity and purity before blending. Aggregate purity and endotoxin are independently tested per batch.
Each component peptide is documented in its own monograph in the COA Library for reference.
Identity & Specifications
Sequence
CJC-1295 (No DAC) · Ipamorelin
Length
2-component blend
Formula
Multi-component
Mol. weight
Aggregate
CAS
— (blend)
PubChem
— (blend)
Purity (HPLC)
≥ 98.5%
Endotoxin (LAL)
0.23 EU/mg
Reconstitution
Bacteriostatic water
Storage
−20°C, sealed
Certificate of Analysis · Lot CB26-04-009
| Parameter | Method | Spec | Result |
|---|---|---|---|
| Identity | ESI-MS | Conforms | Pass |
| Purity | HPLC-UV 220 nm | ≥ 98.0% | 98.5% |
| Endotoxin | LAL kinetic | < 0.5 EU/mg | 0.23 EU/mg |
| Bioburden | Microbial count | < 100 CFU/g | < 10 CFU/g |
| Water content | Karl Fischer | ≤ 6.0% | 4.20% |
| Appearance | Visual | White lyophilized cake | Conforms |
Selected References
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab, 2006.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998.
- Bowers CY. GH releasing peptides — structure and kinetics. J Pediatr Endocrinol Metab, 1993.
- Sigalos JT, Pastuszak AW. The safety and efficacy of GH secretagogues. Sex Med Rev, 2018.
- Component certificates of analysis are issued individually and bundled with each blend lot.
Recent Research Highlights
—
CJC-1295 Component
Teichman et al.
See CJC-1295 (No DAC) monograph for component-specific literature.
—
Ipamorelin Component
Raun et al.
See Ipamorelin monograph for component-specific literature.
—
Combination Pharmacokinetics
Various
Studies of paired-administration kinetics in pre-clinical research.
⊕
3rd Party Tested
Independent lab
≥98%
HPLC Purity
+ ESI-MS
LAL
Endotoxin
LAL kinetic
§
Lot-traceable
In COA library
§ Research-Use Compliance
This compound is supplied by Crescent Bioresearch LLC for laboratory research and pre-clinical use only. It is not a drug, dietary supplement, food, or cosmetic, and has not been approved by the U.S. Food and Drug Administration for human or veterinary administration, diagnosis, treatment, or prevention of any condition.
The pharmacological, toxicological, and stability properties of this compound have not been fully studied. It must therefore be handled only by personnel trained in laboratory safety practices.
The purchaser bears sole responsibility for ensuring that all handling, storage, and intended use comply with applicable local, state, and federal regulations. Full terms are set out in the RUO Disclaimer and Terms of Service.
